Business Insider13h
Adial Pharmaceuticals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential to outperform over the next 12 months, saying its ...
Business Insider13h
Adial Pharmaceuticals announces topline results from AD04-103 PK study
Adial Pharmaceuticals (ADIL) announced that it has completed a pharmacokinetics, PK, study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, and ...
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...
manilatimes19h
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on ...
manilatimes19h
SAIHEAT to Announce SAIHEAT BASE PLAN 2029 on BIT HEAT DAY
SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...